Herbst RS - Search Results

1

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.

Bell DW, Lynch TJ, Haserlat SM, Harris PL, Okimoto RA, Brannigan BW, Sgroi DC, Muir B, Riemenschneider MJ, Iacona RB, Krebs AD, Johnson DH, Giaccone G, Herbst RS, Manegold C, Fukuoka M, Kris MG, Baselga J, Ochs JS, Haber DA. Bell DW, et al. Among authors: herbst rs. J Clin Oncol. 2005 Nov 1;23(31):8081-92. doi: 10.1200/JCO.2005.02.7078. Epub 2005 Oct 3. J Clin Oncol. 2005. PMID: 16204011 Clinical Trial.

2

Chemotherapy for advanced non-small cell lung cancer.

Herbst RS, Dang NH, Skarin AT. Herbst RS, et al. Hematol Oncol Clin North Am. 1997 Jun;11(3):473-517. doi: 10.1016/s0889-8588(05)70445-7. Hematol Oncol Clin North Am. 1997. PMID: 9209907 Review.

3

Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.

Strauss GM, Lynch TJ, Elias AD, Jacobs C, Herbst R, Leong T, Lynch C, Kwiatkowski DJ, Carey RW, Grossbard ML, Skarin AT. Strauss GM, et al. Semin Oncol. 1997 Aug;24(4 Suppl 12):S12-73-S12-80. Semin Oncol. 1997. PMID: 9331127 Clinical Trial.

4

Gemcitabine and vinorelbine combinations in the treatment of non-small cell lung cancer.

Herbst RS, Lilenbaum R. Herbst RS, et al. Semin Oncol. 1999 Oct;26(5 Suppl 16):67-70; discussion 71-2. Semin Oncol. 1999. PMID: 10585011 Review.

5

Differential expression of E-cadherin and type IV collagenase genes predicts outcome in patients with stage I non-small cell lung carcinoma.

Herbst RS, Yano S, Kuniyasu H, Khuri FR, Bucana CD, Guo F, Liu D, Kemp B, Lee JJ, Hong WK, Fidler IJ. Herbst RS, et al. Clin Cancer Res. 2000 Mar;6(3):790-7. Clin Cancer Res. 2000. PMID: 10741698

6

Lung cancer in patients under age 40.

Skarin AT, Herbst RS, Leong TL, Bailey A, Sugarbaker D. Skarin AT, et al. Among authors: herbst rs. Lung Cancer. 2001 Jun;32(3):255-64. doi: 10.1016/s0169-5002(00)00233-6. Lung Cancer. 2001. PMID: 11390007

7

Emerging therapies in non-small-cell lung cancer.

Khuri FR, Herbst RS, Fossella FV. Khuri FR, et al. Among authors: herbst rs. Ann Oncol. 2001 Jun;12(6):739-44. doi: 10.1023/a:1011197500223. Ann Oncol. 2001. PMID: 11484947 Free article. Review.

8

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.

Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Albanell J, et al. J Clin Oncol. 2002 Jan 1;20(1):110-24. doi: 10.1200/JCO.2002.20.1.110. J Clin Oncol. 2002. PMID: 11773160 Clinical Trial.

9

ZD1839: targeting the epidermal growth factor receptor in cancer therapy.

Herbst RS. Herbst RS. Expert Opin Investig Drugs. 2002 Jun;11(6):837-49. doi: 10.1517/13543784.11.6.837. Expert Opin Investig Drugs. 2002. PMID: 12036427 Review.

10

Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results.

Zinner RG, Kim J, Herbst RS. Zinner RG, et al. Among authors: herbst rs. Lung Cancer. 2002 Jul;37(1):17-27. doi: 10.1016/s0169-5002(02)00035-1. Lung Cancer. 2002. PMID: 12057863 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

426 results

Search Page